JAK2 and dermatomyositis: On the one hand, ruxolitinib significantly improved the clinical symptoms of DM, providing new evidence for the efficacy of ruxolitinib in treating DM; on the other hand, the special feature of this case was that the patient had a JAK2 V617F mutation, which may be one of the reasons for the excellent therapeutic effect of ruxolitinib.